DNLI - CIK 0001714899
The table below shows Denali Therapeutics Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$412.60M | -$347.69M | -$357.99M | -$244.72M | -$211.39M | $416.15M |
| Capital expenditure | $9.50M | $15.91M | $12.94M | $17.83M | $8.50M | $3.10M |
| Investing cash flow | $255.28M | -$88.76M | $249.31M | -$141.39M | -$21.63M | -$623.21M |
| Dividends paid | - | - | - | - | - |
Denali Therapeutics Inc. reported operating cash flow of -$412.60M for fiscal year 2025. That is down 18.7% from -$347.69M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$71.91M (FY 2016) to -$412.60M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $189.22M | $484.30M | $17.82M | $310.67M | $19.35M | $634.75M |